Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 1412

1.

Graft-vs.-lymphoma effect in various histologies of non-Hodgkin's lymphoma.

Maloney DG.

Leuk Lymphoma. 2003;44 Suppl 3:S99-105. Review.

PMID:
15202532
[PubMed - indexed for MEDLINE]
3.

Non-myeloablative hematopoietic stem cell transplantation (NST) in the treatment of human malignancies: from animal models to clinical practice.

Shimoni A, Nagler A.

Cancer Treat Res. 2002;110:113-36. Review.

PMID:
11908195
[PubMed - indexed for MEDLINE]
5.

Allogeneic cell therapy for patients who relapse after autologous stem cell transplantation.

Porter DL, Luger SM, Duffy KM, Stadtmauer EA, Laport G, Schuster SJ, Orloff G, Tsai D, McDaid K, Kathakali A, Leonard DG, Antin JH.

Biol Blood Marrow Transplant. 2001;7(4):230-8.

PMID:
11349810
[PubMed - indexed for MEDLINE]
6.
7.

Non-myeloablative transplants for malignant disease.

Storb RF, Champlin R, Riddell SR, Murata M, Bryant S, Warren EH.

Hematology Am Soc Hematol Educ Program. 2001:375-91. Review.

PMID:
11722994
[PubMed - indexed for MEDLINE]
Free Article
8.

The allogeneic effect in non-Hodgkin's lymphoma.

Goldstone AH, Kottaridis PD.

Leuk Lymphoma. 2003;44 Suppl 3:S91-7. Review.

PMID:
15202531
[PubMed - indexed for MEDLINE]
9.

Allogeneic hematopoietic cell transplantation without myeloablative conditioning for patients with advanced hematologic malignancies.

Gürman G, Arat M, Ilhan O, Konuk N, Beksaç M, Celebi H, Ozcan M, Arslan O, Ustün C, Akan H, Uysal A, Koç H.

Cytotherapy. 2001;3(4):253-60.

PMID:
12171713
[PubMed - indexed for MEDLINE]
10.

Reliable engraftment, low toxicity, and durable remissions following allogeneic blood stem cell transplantation with minimal conditioning.

Kobbe G, Schneider P, Aivado M, Zohren F, Schubert D, Fenk R, Neumann F, Kronenwett R, Pape H, Rong A, Royer-Pokora B, Hildebrandt B, Germing U, Gattermann N, Heyll A, Haas R.

Exp Hematol. 2002 Nov;30(11):1346-53.

PMID:
12423689
[PubMed - indexed for MEDLINE]
11.

Autografting followed by nonmyeloablative immunosuppressive chemotherapy and allogeneic peripheral-blood hematopoietic stem-cell transplantation as treatment of resistant Hodgkin's disease and non-Hodgkin's lymphoma.

Carella AM, Cavaliere M, Lerma E, Ferrara R, Tedeschi L, Romanelli A, Vinci M, Pinotti G, Lambelet P, Loni C, Verdiani S, De Stefano F, Valbonesi M, Corsetti MT.

J Clin Oncol. 2000 Dec 1;18(23):3918-24.

PMID:
11099321
[PubMed - indexed for MEDLINE]
Free Article
12.

Second allogeneic stem cell transplantation using nonmyeloablative conditioning for patients who relapsed or developed secondary malignancies following autologous transplantation.

Nagler A, Or R, Naparstek E, Varadi G, Slavin S.

Exp Hematol. 2000 Sep;28(9):1096-104.

PMID:
11008023
[PubMed - indexed for MEDLINE]
13.

Reduced intensity conditioning: enhanced graft-versus-tumor effect following dose-reduced conditioning and allogeneic transplantation for refractory lymphoid malignancies after high-dose therapy.

Mohty M, Fegueux N, Exbrayat C, Lu ZY, Legouffe E, Quittet P, Lopez-Martinez E, Latry P, Avinens O, Hertog C, Klein B, Eliaou JF, Rossi JF.

Bone Marrow Transplant. 2001 Aug;28(4):335-9.

PMID:
11571504
[PubMed - indexed for MEDLINE]
Free Article
14.
15.

Allogeneic peripheral blood stem cell transplantation for high-risk non-Hodgkin's lymphoma.

Seropian S, Bahceci E, Cooper DL.

Bone Marrow Transplant. 2003 Oct;32(8):763-9.

PMID:
14520419
[PubMed - indexed for MEDLINE]
16.

Allogeneic hematopoietic transplantation for mantle-cell lymphoma: molecular remissions and evidence of graft-versus-malignancy.

Khouri IF, Lee MS, Romaguera J, Mirza N, Kantarjian H, Korbling M, Albitar M, Giralt S, Samuels B, Anderlini P, Rodriguez J, von Wolff B, Gajewski J, Cabanillas F, Champlin R.

Ann Oncol. 1999 Nov;10(11):1293-9.

PMID:
10631455
[PubMed - indexed for MEDLINE]
Free Article
17.

High-dose carmustine, etoposide, and cyclophosphamide followed by allogeneic hematopoietic cell transplantation for non-Hodgkin lymphoma.

Law LY, Horning SJ, Wong RM, Johnston LJ, Laport GG, Lowsky R, Shizuru JA, Blume KG, Negrin RS, Stockerl-Goldstein KE.

Biol Blood Marrow Transplant. 2006 Jul;12(7):703-11.

PMID:
16785059
[PubMed - indexed for MEDLINE]
18.

Comparison of reduced-intensity and conventional myeloablative regimens for allogeneic transplantation in non-Hodgkin's lymphoma.

Rodriguez R, Nademanee A, Ruel N, Smith E, Krishnan A, Popplewell L, Zain J, Patane K, Kogut N, Nakamura R, Sarkodee-Adoo C, Forman SJ.

Biol Blood Marrow Transplant. 2006 Dec;12(12):1326-34.

PMID:
17162215
[PubMed - indexed for MEDLINE]
19.

Allogeneic hematopoietic stem cell transplantation (HSCT) after reduced intensity conditioning.

Servais S, Baron F, Beguin Y.

Transfus Apher Sci. 2011 Apr;44(2):205-10. doi: 10.1016/j.transci.2011.01.019. Epub 2011 Feb 22. Review.

PMID:
21345734
[PubMed - indexed for MEDLINE]
20.

The role of purine analogues in low-intensity regimens with allogeneic hematopoietic stem cell transplantation.

Foss FM.

Semin Hematol. 2006 Apr;43(2 Suppl 2):S35-43. Review.

PMID:
16549113
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk